Dong-A ST and Seoul National University School of Advanced Convergence Science and Technology Sign Agreement for AI-Based New Drug Development

Accelerating Next-Generation Drug Development Using AI

Dong-A ST announced on the 22nd that it has signed a business agreement for AI-based new drug development with the School of Advanced Convergence Science and Technology at Seoul National University at its headquarters in Dongdaemun-gu, Seoul.

Jaehoon Jung, President of Dong-A ST, and Kyungsoo Kim, Professor at the School of Advanced Convergence Science at Seoul National University, are taking a commemorative photo after signing a business agreement for AI-based new drug development. Dong-A ST

The goal of this agreement is to accelerate next-generation drug development using AI technology. It was established to create a joint research system that combines Dong-A ST's clinical data and drug development expertise with the School of Advanced Convergence Science and Technology's foundational AI technology.

The two organizations will cooperate in areas including AI-based new drug development and joint research on the digital transformation of research data. In addition, this agreement will serve as an opportunity to launch an internship program for master's and doctoral students at Seoul National University to nurture next-generation talent in AI-driven drug development. In the medium and long term, the partnership aims to expand into a broader industry-academia collaboration system.

The School of Advanced Convergence Science and Technology at Seoul National University has developed general-purpose foundational AI technologies and core algorithms applicable to a wide range of fields. Through accumulated research achievements and technical expertise, the school has established its own competitive edge in AI technology. By combining the AI technology of the School of Advanced Convergence Science and Technology with Dong-A ST's drug assets, clinical data, and drug development capabilities, the partnership is expected to further strengthen global competitiveness in new drug development and establish an AI-based drug development platform.

Professor Kyungsoo Kim of the School of Advanced Convergence Science and Technology at Seoul National University said, "As demonstrated by the Nobel Prize-winning AlphaFold and recent clinical successes, commercially viable drug development AI is only now entering its true beginning phase. In this context, it is more important than ever to nurture advanced talent capable of professionally integrating AI, digital healthcare, biomedical science, and drug development, as well as to assemble top-tier faculty in each field."

He added, "With all these capabilities, the School of Advanced Convergence Science and Technology at Seoul National University, together with Dong-A ST, Korea's leading pharmaceutical company, will take the lead in developing foundational technologies aimed at global commercialization and pioneering the entry of new drugs into the world market."

Jaehoon Jung, President of Dong-A ST, stated, "AI is a core technology that is transforming the paradigm of new drug development. Through collaboration with Seoul National University, we will add new innovative momentum to Dong-A ST's research and development capabilities. By working together, we will accelerate AI-based drug development and continuously create innovative and competitive new drugs for the global market."

This content was produced with the assistance of AI translation services.